Investment Rating - The report maintains a "Recommended" rating for the company [2] Core Insights - The company achieved a revenue of 15.213 billion yuan in 2025, representing a year-on-year growth of 26.46%. The net profit attributable to shareholders reached 1.764 billion yuan, with a growth of 19.87% [7] - The company has significantly increased its R&D investment to 883 million yuan in 2025, a year-on-year increase of 38.04%, which is notably higher than the revenue growth rate. The total number of patents held by the company and its subsidiaries reached 792, an increase of 51.72% year-on-year [7] - The company is optimizing its global production capacity, with adjustments in its investment projects in Southeast Asia and the U.S., demonstrating strong risk response and resource integration capabilities [7] - The robotics business is transitioning from planning to implementation, with a clear product matrix and commercialization path. The company has established a joint venture focusing on key components of humanoid robots [7] - The company is expected to achieve revenues of 20.386 billion, 25.774 billion, and 31.602 billion yuan in 2026, 2027, and 2028, respectively, with corresponding net profits of 2.462 billion, 3.175 billion, and 3.872 billion yuan [7][8] Financial Projections - Revenue and net profit projections for 2026-2028 indicate growth rates of 34.0%, 26.4%, and 22.6% for revenue, and 39.6%, 29.0%, and 21.9% for net profit, respectively [2][8] - The projected earnings per share for 2026, 2027, and 2028 are 8.93 yuan, 11.52 yuan, and 14.04 yuan, respectively [2][8] - The company’s price-to-earnings (P/E) ratio is projected to decrease from 28 in 2025 to 20 in 2026, 15 in 2027, and 13 in 2028, indicating an improving valuation [2][8]